EPO and myeloproliferative neoplasm: The entities to be excluded are AML-myelodysplasia-related changes (AML-MRC), therapy-related AML (t-AML), AML with erythroblast proliferation and recurrent genetic abnormalities, erythroblast phase of myeloproliferative neoplasms (MPNs) and reactive erythroid hyperplasia after erythropoietin (EPO) treatment [2].